Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | S1PR4 | O95977 | 2/20 | 1.00 |
| ▸ | S1PR1 | P21453 | 2/20 | 1.00 |
| ▸ | MITF | O75030 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | XBP1 | P17861 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27367235 | 0.86 | SMN1; SMN2 (0.74) | RAB9ASMN1; SMN2NPC1PAX8HTT | |
| SCHEMBL4672474 | 0.85 | RAB9A (0.74) | RAB9ASMN1; SMN2NPC1PAX8HTT | |
| SCHEMBL4136494 | 0.84 | NPC1 (0.75) | RAB9ASMN1; SMN2NPC1PAX8HTT | |
| SCHEMBL31735886 | 0.84 | RAB9A (0.72) | RAB9ASMN1; SMN2NPC1PAX8HTT | |
| Hydrochloric Acid SCHEMBL4129456 | 0.83 | NPC1 (0.73) | RAB9ASMN1; SMN2NPC1PAX8HTT | |
| SCHEMBL24303253 | 0.82 | NPC1 (0.70) | RAB9ASMN1; SMN2NPC1PAX8HTT | |
| SCHEMBL3984192 | 0.82 | RAB9A (0.70) | RAB9ASMN1; SMN2NPC1PAX8HTT | |
| SCHEMBL9768416 | 0.82 | RAB9A (0.70) | RAB9ASMN1; SMN2NPC1PAX8HTT | |
| Pyrazon SCHEMBL1858918 | 0.82 | RAB9A (0.70) | RAB9ASMN1; SMN2NPC1PAX8HTT | |
| SCHEMBL4648855 | 0.82 | RAB9A (0.70) | RAB9ASMN1; SMN2NPC1PAX8HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180305345-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ONCOLYTIC VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2018-10-25 | — | — | US | claimed |
| EP-3250550-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | Ottawa Hospital Research Institute (CA) | 2017-12-06 | — | — | EP | claimed |
| WO-2016119051-A1 | COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATION | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-08-04 | — | — | WO | claimed |
| WO-2016119052-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ONCOLYTIC VIRUS EFFICACY | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2016-08-04 | — | — | WO | claimed |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. | 2011-11-03 | — | — | US | claimed |
| US-7968711-B2 | Isoprenyl-3-methylcyclohex-2-enyl)benzene-1,3-diol, 2-(3,5-Difluorophenyl)-5-hydroxypyridazin-3-one, 4-Bromo-2-(2,5-dichlorophenyl)-5-hydroxypyridazin-3-one; glaucoma or ocular hypertension | ALLERGAN, INC. (US) | 2011-06-28 | — | — | US | claimed |
| CN-101747322-A | Pyridazinone derivatives with 1,2,4-triazole schiff base, preparation method and application thereof | UNIV GUIZHOU | 2010-06-23 | — | — | CN | claimed |
| EP-2123264-A1 | Heterocyclic derivatives as abnormal cannabidiols agents for lowering intraocular pressure | Allergan, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| EP-1165520-B1 | METHOD FOR PRODUCING 4-AMINO-5-CHLORO-1-PHENYL PYRIDAZINONE | BASF SE (DE) | 2009-05-20 | — | — | EP | claimed |
| US-6538135-B1 | Method for producing 4-amino-5-chloro-1-phenyl pyridazinone-(6) | BASF AKTIENGESELLSCHAFT (DE) | 2003-03-25 | — | — | US | claimed |
| US-4454318-A | USING HYDROXY CONTAINING CATALYSTS | BASF AKTIENGESELLSCHAFT (DE) | 1984-06-12 | — | — | US | claimed |
| EP-0028359-B1 | METHOD FOR PRODUCING 4-CHLORO-5-AMINO-2-PHENYL-3(2H)-PYRIDAZINONE FROM 4,5-DICHLORO-2-PHENYL-3(2H)-PYRIDAZINONE AND AMMONIA | BASF Aktiengesellschaft (DE) | 1984-04-11 | — | — | EP | claimed |
| EP-0026847-B1 | PROCESS FOR PREPARING 4-AMINO-5-CHLORO-1-PHENYLPYRIDAZONE-(6) | BASF Aktiengesellschaft (DE) | 1982-06-23 | — | — | EP | claimed |
| US-4297493-A | Manufacture of 4-amino-5-chloro-1-phenylpyridaz-6-one using aqueous phenol-4-sulfonic acid | BASF AKTIENGESELLSCHAFT (DE) | 1981-10-27 | — | — | US | claimed |
| WO-1981001288-A1 | METHOD FOR PRODUCING 4-CHLORO-5-AMINO-2-PHENYL-3(2H)-PYRIDAZINONE FROM 4,5-DICHLORO-2-PHENYL-3(2H)-PYRIDAZINONE AND AMMONIA | KOEGE KEMISK VAERK (DK) | 1981-05-14 | — | — | WO | claimed |
| EP-0028359-A1 | Method for producing 4-chloro-5-amino-2-phenyl-3(2H)-pyridazinone from 4,5-dichloro-2-phenyl-3(2H)-pyridazinone and ammonia | BASF Aktiengesellschaft (DE) | 1981-05-13 | — | — | EP | claimed |
| US-4237287-A | DIAZOTIZATION WITH SODIUM NITRITE AND CHLORINATION WITH THIONYL CHLORIDE | OXON ITALIA S.P.A. (IT) | 1980-12-02 | — | — | US | claimed |
| US-20250170283-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-4002751-A | SLEEP INDUCERS, CNS DEPRESSANTS | SANDOZ, INC. (US) | 1977-01-11 | — | — | US | disclosed |
| US-3935210-A | Preparation of 1-aryl-4,5-dihalo-pyridazone-6 | SANDOZ, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170283-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | RAB9A 2539/4885SMN1; SMN2 699/4885NPC1 221/4885 |
| US-20180305345-A1 | COMPOSITIONS AND METHODS FOR ENHANCING ONCOLYTIC VIRUS EFFICACY | TP53, HAVCR2, TSG101 | RAB9A 1623/4885SMN1; SMN2 204/4885NPC1 457/4885 |
| US-20110269715-A1 | ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | CNR2, CNR1, PTGIR | RAB9A 342/4885SMN1; SMN2 4837/4885NPC1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.